Active, not recruitingPhase 2NCT03279692

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

Studying Meningioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts General Hospital
Principal Investigator
Priscilla Brastianos, MD, MD, PHD
Massachusetts General Hospital
Intervention
Pembrolizumab(drug)
Enrollment
26 enrolled
Eligibility
18 years · All sexes
Timeline
20172026

Study locations (2)

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03279692 on ClinicalTrials.gov

Other trials for Meningioma

Additional recruiting or active studies for the same condition.

See all trials for Meningioma

← Back to all trials